EndoStim hopes to raise $36 million in an initial public offering to support development of a pacemaker-like device to treat severe gastroesophageal reflux disease.
EndoStim said it hopes to raise nearly $36 million in an initial public offering, with plans to plow $10 million into clinical studies of its system to treat severe gastroesophageal reflux disease and another $14 million to commercialize the system.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/Zrx2xq
Cap comentari:
Publica un comentari a l'entrada